Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Is disrupting cardiac fibrosis a rational strategy for treating heart disease?

Nature Cardiovascular Research volume 1, pages 405–407 (2022)Cite this article

Subjects

Fibrosis is a common sequela of cardiovascular disease that results in structural and functional changes. Targeting the subsets of pathogenic cardiac fibroblasts may be an attractive option for reducing morbidity that is associated with heart disease, but the timing, specificity and extent to which fibroblast-targeting therapies might be used is still debated.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Potential opportunities for targeting cardiac fibroblasts.

References

  1. Tallquist, M. D. et al. Nat. Rev. Cardiol. 14, 484–491 (2017).

    Article  Google Scholar 

  2. Plikus, M. V. et al. Cell 184, 3852–3872 (2021).

    Article  CAS  Google Scholar 

  3. Bowers, S. L. K. et al. Nat. Cardiovasc. Res. 1, 312–321 (2022).

    Article  Google Scholar 

  4. Muhl, L. et al. Nat. Commun. 11, 3953 (2020).

    Article  CAS  Google Scholar 

  5. Fu, X. et al. J. Clin. Invest. 128, 2127–2143 (2018).

    Article  Google Scholar 

  6. Farbehi, N. et al. eLife 8, e43882 (2019).

    Article  Google Scholar 

  7. Forte, E. et al. Cell Rep. 30, 3149–3163.e6 (2020).

    Article  CAS  Google Scholar 

  8. Peyser, R. et al. Am. J. Resp. Cell Mol. 61, 74–85 (2019).

    Article  CAS  Google Scholar 

  9. Kanisicak, O. et al. Nat. Commun. 7, 12260 (2016).

    Article  CAS  Google Scholar 

  10. Aghajanian, H. et al. Nature 573, 430–433 (2019).

    Article  CAS  Google Scholar 

  11. Drago, J. Z. et al. Nat. Rev. Clin. Oncol. 18, 327–344 (2021).

    Article  Google Scholar 

  12. Sheppard, D. Ann. Am. Thorac. Soc. 12, S21–S23 (2015).

    Article  Google Scholar 

  13. Frangogiannis, N. G. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-021-00646-w (2022).

  14. Schafer, S. et al. Nature 552, 110–115 (2017).

    Article  CAS  Google Scholar 

  15. López, B. et al. Nat. Rev. Cardiol. 18, 479–498 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Cardiovascular Research, University of Hawaii, Honolulu, Hawaii, USA

    Akitoshi Hara & Michelle D. Tallquist

Authors
  1. Akitoshi Hara
    View author publications

    Search author on:PubMed Google Scholar

  2. Michelle D. Tallquist
    View author publications

    Search author on:PubMed Google Scholar

Contributions

Both authors prepared the Comment.

Corresponding author

Correspondence to Michelle D. Tallquist.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hara, A., Tallquist, M.D. Is disrupting cardiac fibrosis a rational strategy for treating heart disease?. Nat Cardiovasc Res 1, 405–407 (2022). https://doi.org/10.1038/s44161-022-00069-x

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s44161-022-00069-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing